{"entity":{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","aka":[],"tldr":"The PD-1 antibody nivolumab produced responses in about seven in ten patients whose Hodgkin lymphoma had returned after a stem cell transplant, with responses lasting well over a year, confirming the exquisite sensitivity of this lymphoma to checkpoint blockade.","summary":"Multicohort single-arm phase 2 study of 243 patients with classical Hodgkin lymphoma relapsed or refractory after autologous stem cell transplantation, treated with nivolumab; cohorts were brentuximab-naive, brentuximab after transplant, and brentuximab before and/or after transplant.\n\nWith extended follow-up the objective response rate was 69 percent, median duration of response 16.6 months and median progression-free survival 14.7 months; responses were independent of PD-L1 expression level, and the safety profile matched other nivolumab studies. The data underpinned regulatory approval of nivolumab in this setting.","asOf":"2026-09-18","links":[{"label":"J Clin Oncol 2018","url":"https://doi.org/10.1200/JCO.2017.76.0793"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29584546/"}],"tags":[],"related":[],"cancers":["relapsed-refractory-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-205"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/JCO.2017.76.0793","pmid":"29584546","authors":"Armand P, Engert A, Younes A, et al.","paperType":"observational","findings":["Objective response 69 percent; median duration of response 16.6 months; median progression-free survival 14.7 months."],"whatItMeans":"Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).","caveats":["Single-arm; no randomised comparison with brentuximab vedotin.","Complete responses were a minority and most patients eventually progressed."],"changedPractice":true,"participants":243},"route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/","neighbours":{"cancer":[{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}